Speciality Medicines SME IPO | Issue Dates, Listing, Financials & Analysis
Latest Grey Market Premium & IPO Details
Speciality Medicines IPO 2026 – Key Info & Highlights
Speciality Medicines SME IPO 2026: Check issue dates, price band ₹117-124, minimum application, tentative BSE SME listing on March 30, 2026, and key financials & analysis for investors.
📌 IPO Details
| Company Name | Speciality Medicines IPO |
|---|---|
| Sector / Industry | Pharmaceuticals / Healthcare |
| IPO Open Date | 20-03-2026 |
| IPO Close Date | 24-03-2026 |
| Allotment Date | 25-03-2026 |
| Refund Date | 27-03-2026 |
| Share Credit Date | 27-03-2026 |
| Listing Date | 30-03-2026 |
| Price Band | ₹117 - ₹124 |
| Lot Size | 1000 Shares |
| Min Investment | ₹2,48,000 (2 lots) |
| Total Issue Size | ₹29.14 Cr |
| Reserved for Market Maker | ₹1.86 Cr |
| Net Issue Size | ₹27.28 Cr |
| Fresh Issue | ₹27.28 Cr |
| IPO Listing At | BSE SME |
| DRHP | View DRHP |
| RHP | View RHP |
| Final Prospectus | https://www.bsesme.com/download/354383/SME_IPO%20BasisOfAllotment/Prospectus_20260325151551.pdf |
| Issue Type | Book Build Issue |
| Face Value | ₹10 Per Equity Share |
* All Dates are provisional
Quota Allocation
| Category | Allocation (%) |
|---|---|
| Retail Investors | 46.38% |
| QIB (Qualified Institutional Buyers) | 0.89% |
| HNI (High Net Worth Individuals) | 46.34% |
| Reserved for Market Maker | 6.38% |
📈 Grey Market Premium (GMP) Day-wise Trend
| GMP Date | GMP Price | Trend | Estimated Listing Price | Estimated Profit* | Last Updated |
|---|---|---|---|---|---|
| 30-03-2026 | ₹0.00 | - | ₹0.00 | ₹0.00 | 30-03-2026 09:53 |
| 29-03-2026 | ₹0.00 | - | ₹0.00 | ₹0.00 | 29-03-2026 23:20 |
| 28-03-2026 | ₹0.00 | - | ₹0.00 | ₹0.00 | 28-03-2026 23:20 |
📝 About Speciality Medicines
Incorporated in 2021, Speciality Medicines Limited (SML) is a leading Indian pharmaceutical company engaged in the marketing, distribution, and export of specialty pharmaceuticals. The company focuses on high-cost oral and injectable medications used to treat complex and chronic conditions, serving both domestic and international markets.
SML’s portfolio includes a wide range of finished formulations such as capsules, creams, eye drops, gels, infusions, inhalations, inhalers, injections, nasal sprays, ointments, ophthalmic solutions, oral solutions, oral suspensions, sachets, suspensions, and tablets. The company’s products span critical therapeutic areas including oncology, immunology, neurology, and rare diseases, catering to the specialized healthcare needs of patients worldwide.
As of July 31, 2024, Speciality Medicines Limited offers over 650 products under the unregistered category and continues to expand its portfolio with human and animal medicines, vaccines, and plasma products. All products are sourced from manufacturers adhering to global quality standards such as EUGMP and PICS, ensuring safety, efficacy, and compliance with international regulations.
Through its extensive distribution network, SML has established a trusted reputation with clients across more than 20 states in India and over 35 countries worldwide. The company is also actively pursuing global product registrations, with 127 products under registration in 8 countries and 1 plasma product registered in Bolivia as of July 31, 2024.
Speciality Medicines Limited operates with a dedicated team of 20 permanent employees across various departments, ensuring smooth and efficient operations while supporting the company’s growth strategy. The company’s mission is to enhance patient outcomes and quality of life by providing access to advanced medical products and specialized therapies, positioning itself as a trusted partner in healthcare both domestically and globally.
Speciality Medicines Revised Financials
Financial Summary (Last 4 Periods)
| Period Ended | Assets | Total Income | Profit After Tax | Net Worth | Reserves & Surplus | Total Borrowings |
|---|---|---|---|---|---|---|
| 31 May 2024 | 26.44 | 8.37 | +2.30 | 19.23 | 14.08 | 2.53 |
| 31 Mar 2024 | 23.43 | 27.66 | +4.55 | 16.61 | 11.50 | 2.86 |
| 31 Mar 2023 | 13.26 | 23.26 | +1.69 | 5.87 | 2.05 | 3.64 |
| 31 Mar 2022 | 5.78 | 40.45 | +1.48 | 1.93 | 1.72 | 1.18 |
Note: Positive figures indicate profit. All amounts are reported in ₹ Crore.
Speciality Medicines Ltd. – Objects of Issue
- Setting up of Research and Development (R&D) Centre – At Revenue City Survey No. RV1/NA/61/1/50, Moje, Manda, Tal. Umargam, Dist. Valsad, Gujarat ₹12.68 Cr
- Product Registration in International Markets and Product Development – For sale in international markets ₹2.99 Cr
- Funding for Marketing and Promotional Activities – To expand brand visibility and sales ₹1.66 Cr
- To Meet Working Capital Requirements – For day-to-day operational needs ₹8.00 Cr
- General Corporate Purposes – For other corporate activities -
- Total ₹25.33 Cr
Speciality Medicines Ltd. – Key Strengths
- Strong Market Presence – Established player in the specialty pharmaceuticals sector with operations across domestic and international markets.
- Wide Geographic Reach – Well‑developed distribution network serving customers in over 35 countries worldwide.
- Growing Financial Performance – Demonstrated consistent revenue growth and strong profitability, with significant increases in revenue and PAT over recent years.
- Product Portfolio Diversity – Offers a diverse range of specialty pharmaceutical products addressing critical therapeutic areas such as oncology, immunology, and neurology.
- Experienced Promoters – Backed by a management team with deep industry knowledge and experience in pharmaceutical marketing and distribution.
Speciality Medicines Ltd. – Key Risk Factors
- No Prior Market for Shares – This is the company’s first public issue, and there is no existing market for its shares. There is no assurance of active trading or liquidity after listing, and the share price may fluctuate widely.
- Equity Investment Risk – Investments in equity shares involve high risk, and you should only invest if you can afford to lose part or all of your investment. Potential investors must rely on their own evaluation of the company and the IPO terms before investing.
- Regulatory & Compliance Risk – The pharmaceutical industry is highly regulated. Delays or failure to obtain required approvals or maintain compliance could materially affect business operations and financial performance.
- Competition Risk – The company faces competition from organized and unorganized players in the specialty pharmaceutical distribution business. Some competitors may have greater financial resources, extensive distribution networks, or stronger market positions, which could impact pricing and market share.
- Dependence on Third‑Party Suppliers – Speciality Medicines sources products from third-party manufacturers. Any disruption in supplier relationships, quality issues, or manufacturing delays could affect product availability and sales.
Company Information
Founded in: 05 February 2021
MD / CEO: Parthkumar Babulal Goyani (Managing Director)
Registered Office: 913, One World West, S. No. 396, FP 119, Village‑Vejalpur, Ahmedabad City, Ahmedabad, Gujarat – 380051, India.
Website: www.specialitymedicine.com
Phone: +91‑22‑4604 5344
Email: investors.grievances@specialitymedicine.com
IPO Quick Info
20 Mar 2026
24 Mar 2026
Upcoming
Lead Manager(s)
- Ekadrisht Capital Pvt.Ltd.
Frequently Asked Questions
Speciality Medicines focuses on specialty pharmaceuticals, including oral and injectable formulations in oncology, immunology, neurology, and rare diseases.